prikaz prve stranice dokumenta Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
  Preuzmi
PDF 420.16 KB
Znanstveni rad - Izvorni znanstveni rad
Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
International Journal of Environmental Research and Public Health, 17 (2020), 18; 6566. https://doi.org/10.3390/ijerph17186566
Lekšić, Gloria; Baretić, Maja; Ivanišević, Marina; Jurišić Eržen, Dubravka

Citirajte ovaj rad

Lekšić, G., Baretić, M., Ivanišević, M. i Jurišić Eržen, D. (2020). Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?. International Journal of Environmental Research and Public Health, 17. (18). doi: 10.3390/ijerph17186566

Lekšić, Gloria, et al. "Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?." International Journal of Environmental Research and Public Health, vol. 17, br. 18, 2020. https://doi.org/10.3390/ijerph17186566

Lekšić, Gloria, Maja Baretić, Marina Ivanišević i Dubravka Jurišić Eržen. "Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?." International Journal of Environmental Research and Public Health 17, br. 18 (2020). https://doi.org/10.3390/ijerph17186566

Lekšić, G., et al. (2020) 'Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?', International Journal of Environmental Research and Public Health, 17(18). doi: 10.3390/ijerph17186566

Lekšić G, Baretić M, Ivanišević M, Jurišić Eržen D. Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?. International Journal of Environmental Research and Public Health [Internet]. 09.09.2020. [pristupljeno 19.11.2024.];17(18). doi: 10.3390/ijerph17186566

G. Lekšić, M. Baretić, M. Ivanišević i D. Jurišić Eržen, "Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?", International Journal of Environmental Research and Public Health, vol. 17, br. 18, Rujan 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:529488. [Citirano: 19.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:529488
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
AutorGloria Lekšić
AutorMaja Baretić
AutorMarina Ivanišević
AutorDubravka Jurišić Eržen
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Ginekologija i opstetricija
Sažetak (engleski)
Despite widespread use of technology, type one diabetes mellitus (T1DM) is still a great clinical challenge during pregnancy. This study aims to assess how prenatal variables of T1DM patients using continuous subcutaneous insulin infusion (CSII) influence pregnancy outcomes. We performed a retrospective study of 35 patients with T1DM treated with CSII during pregnancy. Alterable preconception variables (A1C, body mass index, basal and bolus insulin dose) were analysed as possible contributors to birth weight and large-for-gestational-age (LGA) prevalence. Inclusion criteria were presence of T1DM for more than two years, A1C < 7.4% and treatment with CSII for at least three months prior to conception. The preconception basal insulin dose and A1C had a significant correlation to the neonatal birth weight (p = 0.01, r = 0.4 and p = 0.04, r = 0.3, respectively) and were significant in regression analysis together contributing 22% of the variance in birth weight percentiles (sig = 0.17, R square = 0.22). Prevalence of LGA was 46%. Women who had LGA neonates also had a higher preconception basal insulin dose compared to women with non-LGA neonates (26 ± 9 vs. 18 ± 7 IU (international units), p = 0.01). The LGA group had a higher preconception A1C, but it did not reach statistical significance (6.5 ± 0.5% vs. 6.2 ± 0.9%, respectively, p = 0.2). Women with T1DM treated with CSII who had unregulated glycaemia and more basal insulin were at greater risk for development of LGA neonates.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Environmental Research and Public Health
Brojčani podacivol. 17, br. 18, 6566
e-ISSN1660-4601
DOIhttps://doi.org/10.3390/ijerph17186566
URN:NBNurn:nbn:hr:184:529488
Datum objave publikacije2020-09-09
URL dokumentahttps://www.mdpi.com/1660-4601/17/18/6566
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2020-09-28 14:51:26